De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

University of Rome Tor Vergata

Status

Completed

Conditions

Single Transplant

5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS

Treatments

Drug: Immunosuppressive

Study type

Observational

Funder types

Other

Identifiers

NCT05808192

R.S.123.20

Details and patient eligibility

About

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

Full description

A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group).

Enrollment

92 patients

Sex

All

Ages

49 to 89 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

single LT recipients with an attempt of IS withdrawal
minimum 5 years follow-up

Exclusion criteria

Liver transplant combined with other organs
Presence of metabolic syndrome and/or NASH and/or NAFLD as an indication for liver transplantation
Loss of patient to follow-up